No Picture
News

BLUE CROSS BLUE SHIELD OF MASSACHUSETTS EXPEDITES ACCESS TO CARE FOR TEXAS MEMBERS AFFECTED BY SEVERE WEATHER

BOSTON, Jan. 27, 2023 /PRNewswire/ — In response to severe weather in Texas, Blue Cross Blue Shield of Massachusetts (Blue Cross) is expediting access to care for members who may be affected. Blue Cross has more than 8,500 members living in areas under states of emergency. The company is… Click here to view original post… […]

No Picture
News

Bristol Myers, Charles River join Series A funding for iVexSol

Massachusetts-based iVexSol has secured funding to the tune of $23.8 million in its latest Series A round. The new investors include Bristol Myers Squibb, manufacturer Charles River Laboratories and Asahi Kasei Medical. iVexSol is a manufacturer of lentiviral vectors (LVV), used in making gene therapies, and this latest round of…… Click here to view original post… […]

No Picture
News

Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board.

The company launches its website with key pipeline information Regel adds industry leader Andrew Schiermeier, Ph.D to its Board of Directors Regel announces its Scientific Advisory Board chaired by Regel Co-Founder Orrin Devinsky, M.D. CAMBRIDGE, Mass. and BERKELEY, Calif., Jan. 27, 2023… Click here to view original post… […]

No Picture
News

Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy

START-001 study leverages a biomarker-enriched tissue-agnostic approach to evaluate the activity of STAR0602 monotherapy in checkpoint inhibitor refractory advanced solid tumors CAMBRIDGE, Mass., Jan. 27, 2023 /PRNewswire/ — Marengo Therapeutics, Inc., a company pioneering novel… Click here to view original post… […]